MOG and myeloid sarcoma: To date, it remains unknown whether this effect occurs in patients with CNS demyelinating disorders in a functionally meaningful manner, although early development of anti-MOG Ab in MS [23] as well as the pronounced peripheral production of Ab against AQP-4 or MOG in NMO and NMOSD patients [20] highlights this possibility.